Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 50% revenue increase and improved margins. The company turned a net income from a loss, indicating operational improvements. Although risks are acknowledged, the positive financial metrics and strategic initiatives outweigh them. The market cap suggests moderate sensitivity to news, leading to a positive stock price prediction of 2% to 8%.
Key Financial Performance
Revenue $250 million, a 50% increase year-over-year, driven by strong customer acquisition and retention.
Gross Margin 75%, up from 70% last year, due to improved operational efficiencies and cost management.
Net Income $10 million, compared to a loss of $5 million last year, attributed to increased revenue and better cost control.
Operating Cash Flow $30 million, a 20% increase year-over-year, supported by higher profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, including market, competitor, and regulatory expectations, which could cause actual results to vary materially.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on, among other things, our current market, competitors and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We take no obligation to update publicly any forward-looking statement after this call, whether as a result of new information, future events, changes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bank PLC
Barclays Bank
Brian Tanquilut
CEO Yemi
Canaccord Genuity
Craig Hettenbach
Division Brian
Division Craig
Division Eric
Division Glen
Division Justin
Division Ryan
Dudum Co
EST Dudum
Equities Research
Eric Percher
Evercore ISI
Glen Santangelo
ISI Institutional
Inc PM
Institutional Equities
Instructions Newby
Justin Patterson
LLC Research
LLC Stephen
Mahaney Evercore
Maria Ripps
Newby Head
Officer Maria
PLC Research
Research Division
HIMS Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Unknown5-12
The company's international revenue growth is a positive indicator, and the transition to branded products with strong retention is promising. However, the negative impact on gross margins due to restructuring costs and the unclear guidance on future margins and EBITDA dampens the outlook. Additionally, while AI and new category investments show potential, they also introduce uncertainty. Given the market cap of $4.3 billion, the stock is likely to experience a neutral movement, as the positive and negative factors balance each other out.
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Neutral3-2
Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call reveals strong financial performance with a 50% revenue increase and improved margins. The company turned a net income from a loss, indicating operational improvements. Although risks are acknowledged, the positive financial metrics and strategic initiatives outweigh them. The market cap suggests moderate sensitivity to news, leading to a positive stock price prediction of 2% to 8%.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary reveals strong financial performance with optimistic guidance, including a projected revenue growth of 42% to 47% for Q3 2025 and a robust full-year growth outlook. The company is expanding into new markets and specialties, indicating future growth potential. Despite some uncertainties regarding margin contraction, the overall sentiment remains positive due to strategic investments and international expansion plans. The market cap suggests a moderate reaction, leading to a prediction of a 2% to 8% stock price increase.
HIMS Slides
HIMS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
